Skip to content
A3191Assembly2021-2022 SessionSame asS1462

Require Cancer Genetic Testing

Official title

“Relates to dihydropyrimidine dehydrogenase deficiency testing”

Sponsor Patricia FahyAD-109Affects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires testing for dihydropyrimidine dehydrogenase deficiency before certain cancer treatments and mandates insurance coverage for such testing.

Why it matters

  1. Reduces risk of severe or fatal reactions. Testing for dihydropyrimidine dehydrogenase (DPD) deficiency before administering certain chemotherapy drugs (fluoropyrimidines and similar antimetabolites) can prevent life-threatening toxicity in patients who unknowingly lack the enzyme needed to process these drugs.

  2. Promotes equitable access to lifesaving diagnostics. By mandating insurance—including Medicaid—coverage for DPD deficiency testing, the bill ensures that all patients, regardless of income or insurance type, can access this important safety measure prior to cancer treatment.

  3. Standardizes cancer care protocols. The law would require all relevant healthcare providers in New York to implement DPD deficiency testing, reducing variability in care and aligning state practice with emerging clinical recommendations for personalized medicine.

  4. Could impact healthcare costs and outcomes. Early identification of DPD deficiency may prevent costly hospitalizations and medical complications from adverse drug reactions, potentially improving both patient outcomes and controlling long-term healthcare expenditures.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Cancer patients receiving fluoropyrimidines or other antimetabolites

    The bill would require testing for dihydropyrimidine dehydrogenase deficiency before treatment.

  • Physicians and other authorized cancer practitioners

    They would have to test patients for the deficiency before providing these treatments.

  • Health insurers and health service corporations

    Covered policies and contracts would have to cover deficiency testing before oral cancer treatment involving fluoropyrimidines or other antimetabolites.

  • Medicaid administrators

    The bill would require the commissioner to establish standards and guidelines for providing deficiency testing before these cancer treatments under Medicaid.

Headline styles

Require Cancer Genetic Testing

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Patricia Fahy

Assembly Member · Assembly District 109

No co-sponsors yet.

History

  1. Referred to health
  2. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S1462Senate

Require Cancer Drug Safety Testing

In Senate Committee · Health · Sponsor Neil D. Breslin

Impact 6 · Moderate0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

3191

2021-2022 Regular Sessions

IN ASSEMBLY

January 22, 2021

Introduced by M. of A. FAHY -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to requiring dihydropyrimidine dehydrogenase deficiency testing for certain individuals with cancer; to amend the insurance law, in relation to requiring policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; and to amend the social services law, in relation to the provision of dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public health law is amended by adding a new section 2400-a to read as follows:

§ 2400-a. Dihydropyrimidine dehydrogenase deficiency testing. 1. For purposes of this section the following terms shall have the following meanings:

(a) "Antimetabolites" means a substance that interferes with the normal metabolic processes within cells, typically by combining with enzymes.

(b) "Dihydropyrimidine dehydrogenase deficiency" means a condition in which the body cannot break down the nucleotides thymine and uracil.

(c) "Fluoropyrmidine" means a group of substances used to treat cancer through chemotherapy.

2. Every physician or other authorized practitioner who provides fluoropyrmidine or other antimetabolites to individuals diagnosed with cancer shall test for dihydropyrimidine dehydrogenase deficiency prior to such treatment.

§ 2. Subparagraph (A) of paragraph 12-a of subsection (i) of section 3216 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows:

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04207-01-1

A. 3191 2

(A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrmidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 3. Subparagraph (A) of paragraph 12-a of subsection (l) of section 3221 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows:

(A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrmidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 4. Paragraph 1 of subsection (q-1) of section 4303 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows:

(1) Every contract issued by a medical expense indemnity corporation, a hospital service corporation or a health service corporation for delivery in this state that provides medical, major medical or similar comprehensive-type coverage and provides coverage for prescription drugs and for cancer chemotherapy treatment shall provide coverage for prescribed, orally administered anticancer medications used to kill or slow the growth of cancerous cells, and shall provide coverage for dihydropyrimidine dehydrogenase deficiency testing prior to such treatment where such treatment consists of fluoropyrmidine or other antimetabolites. Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for intravenous or injected anticancer medications.

§ 5. The social services law is amended by adding a new section 365-o to read as follows:

§ 365-o. Provision of dihydropyrimidine dehydrogenase deficiency testing. 1. The commissioner shall establish standards and guidelines for the provision of dihydropyrimidine dehydrogenase deficiency testing prior to cancer treatment through fluoropyrmidine or other antimetabolites under the medical assistance program.

2. For purposes of this section:

(a) "Antimetabolites" means a substance that interferes with the normal metabolic processes within cells, typically by combining with enzymes.

A. 3191 3

(b) "Dihydropyrimidine dehydrogenase deficiency" means a condition in which the body cannot break down the nucleotides thymine and uracil.

(c) "Fluoropyrmidine" means a group of substances used to treat cancer through chemotherapy.

§ 6. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.